NC-VERANEX
12.10.2021 15:02:07 CEST | Business Wire | Press release
Veranex , the first concept-to-commercialization global service provider dedicated to the MedTech industry, today announced the acquisition of IMMR , a leading preclinical science organization that provides preclinical research, pathology evaluation and surgical training services to medical technology innovators. IMMR is located in Paris, France.
Formed in June 2021 with global growth investor Summit Partners , Veranex provides the global medical technology industry with comprehensive and integrated solutions and services that accelerate the product life cycle to help improve the lives of patients everywhere. As a result of this acquisition, Veranex gains state-of-the-art, FDA-inspected and AAALAC-accredited facilities and extensive in-house expertise, enhancing Veranex’s services for preclinical studies worldwide.
“We are excited to welcome the world-class and market leader IMMR to Veranex,” said Patrick K. Donnelly , Executive Chairman at Veranex. “Veranex is focused on the needs of the MedTech industry and this acquisition enhances our long-term ability to meet the end-to-end needs of MedTech companies in one organization. Veranex’s clients will benefit from IMMR’s 30-plus years of experience in the design and conduct of preclinical studies, expertise in complex cardiovascular and non-cardiovascular procedures, and state-of-the-art surgical suites and husbandry facilities, all unparalleled for leading successful completion of sophisticated studies with novel interventional or surgical technologies.”
“As part of a combined company with a full range of product development, regulatory, and market access expertise, our partnership with Veranex complements our vision to help clients achieve their objectives and advance important MedTech innovations that significantly improve patient care,” said IMMR Founding Partner and Scientific Director Luc Behr , D.V.M., Ph.D. “IMMR adds another dimension of expertise and services to Veranex to enable and accelerate research in the industry.”
IMMR’s unique, highly efficient, and full service approach — with studies that are carefully planned, expertly conducted to the highest ethical standards, and professionally documented — saves money and reduces time to market.
“IMMR excels in procedures ranging from early feasibility studies through to GLP studies to support global regulatory approvals,” added IMMR Founding Partner and Scientific Director Nicolas Borenstein , D.V.M., Ph.D. “With our expert team of professionals, our worldwide clientele enjoys high success rates with their medical technology innovations.”
For this transaction, financial advisors were Clearwater International and Cain Brothers , a division of KeyBanc Capital Markets, and Gide Loyrette Nouel , a leading international law firm located in Paris, served as legal counsel. Financial terms of the transaction were not disclosed.
About Veranex
Veranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept through to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its integrated and comprehensive solutions unify the entire development process. For more information, visit VeranexSolutions.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom